Tempus AI, Inc. (TEM)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Google Invested in This Hot New Artificial Intelligence (AI) Stock. Should You?
Tempus AI conducted its IPO last week. The healthcare AI company has financial backing from Google.
U.S. IPO Weekly Recap: Precision Medicine IPO Tempus AI Posts A Modest Gain In Its Debut
One large IPO priced this past week, while the other scheduled deal was pulled. Two blank checks also began trading - Tempus AI, Telix Pharmaceuticals, Centurion Acquisition, and Perceptive Capital Solutions, respectively. One nanocap is currently scheduled to list in the week ahead, although some other small issuers may join the calendar throughout the week - Nova Minerals. Street research is expected for one company in the week ahead, and lock-up periods will be expiring for one company.
Tempus AI: Healthcare AI Play Faces Some Challenges From The Start
Tempus AI, Inc, aims to revolutionize precision medicine with AI technology and healthcare data. The promise looks good, as the revenue base is substantial, but unfortunately the same applies to the losses incurred. With revenue growth slowing down dramatically and operating leverage coming to a standstill, I am leaning cautious about Tempus here.
TEM Stock IPO: 7 Things to Know as Tempus AI Starts Trading Today
One of the season's most highly anticipated initial public offerings (IPOs) is taking place today. Tempus AI (NASDAQ: TEM ), a company bringing artificial intelligence (AI) to the data processing space, begins trading today after weeks of anticipation.
Tempus AI announces pricing of US IPO
SoftBank Group-backed Tempus AI announced on Thursday the pricing of its initial public offering of 11.1 million ordinary shares at a price of $37 apiece.
TEM Stock IPO: When Does Tempus AI Go Public? What Is the Tempus AI IPO Price Range?
Tempus AI stock is preparing for an initial public offering ( IPO ) and we have all of the details that traders need to know about before it gets here. Let's get into all of the latest Tempus AI IPO details below ahead of its potential listing this week!
Healthcare-technology company Tempus AI looks to raise $400 million in IPO
Tempus AI Inc. is about to give investors a way to play the intersection of medicine and artificial intelligence.
Tempus AI seeks up to $6.1 bln valuation in US IPO
Tempus AI is targeting a valuation of up to $6.10 billion in its initial public offering in the United States, the genetics testing company said on Wednesday.
